| Exclusion Criteria: | 1) Pregnant or lactating
2) Prior allogeneic bone marrow (or other organ) transplantation
3) Systemic antineoplastic treatment within 21 days preceding the first dose of study treatment. Exceptions requiring a 42-day recovery period from last treatment include: Nitrosoureas, mitomycin C; Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody (21 days if clear evidence of progressive disease)
4) Treatment with radioimmunoconjugates or toxin immunoconjugates such as ibritumomab tiuxetan (Zevalin), or tositumomab (Bexxar®) within 56 days preceding the first dose of study treatment
5) Antineoplastic treatment with glucocorticoids within 21 days preceding the first dose of study treatment
6) Radiotherapy involving <25% of the hematopoietically active bone marrow within 21 days preceding first dose of study treatment
7) Radiotherapy involving >/=25% of the hematopoietically active bone marrow within 42 days preceding first dose of study treatment
8) Major surgery within the 14 days preceding the first dose of study treatment
9) Serious infection within 14 days prior to the first dose of study treatment
10) Life-threatening or uncontrolled medical illness unrelated to cancer
11) Ongoing nausea or vomiting that is Grade 2 or worse in intensity
12) Diarrhea that is Grade 2 or worse in intensity or use of an antimotility agent to control diarrhea to an intensity of Grade 1 or lower level
13) Known GI disease or GI procedures that could interfere with the oral absorption or tolerance of MLN8237. Examples include, but are not limited to, partial gastrectomy, history of small intestine surgery, and celiac disease.
14) History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease
15) Inability to swallow capsules, or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose of MLN8237
16) Newly diagnosed or uncontrolled cancer-related CNS disease
17) Absolute neutrophil count (ANC) <1,500/mm^3
18) Platelet count <75,000/mm^3
19) Measured or estimated creatinine clearance (Cockcroft-Gault formula) <30 mL/minute
20) Bilirubin >1.5 times the ULN or aspartate transaminase (AST)/alanine transaminase (ALT) >2.5 times the ULN. The AST or ALT level may be elevated up to 5 times the ULN if the elevation can be reasonably attributed to the presence of metastatic disease to liver.
21) Diagnosed or treated for another malignancy within 2 years of first dose, or who were previously diagnosed with another malignancy and have any radiographic or biochemical marker evidence of active disease. In the case of prior prostate cancer treated with radiotherapy, the PSA may be detectable, but must be <1 ng/mL. Subjects with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy of any type are not excluded.
22) Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant, including but not limited to clinically important QTc prolongation
23) Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection. Testing is not required in the absence of clinical findings or suspicion.
24) Inability to comply with study visits and procedures |